Irradiator Commissioning and Dosimetry for Assessment of LQ α and β Parameters, Radiation Dosing Schema, and in vivo Dose Deposition.


Journal

Journal of visualized experiments : JoVE
ISSN: 1940-087X
Titre abrégé: J Vis Exp
Pays: United States
ID NLM: 101313252

Informations de publication

Date de publication:
11 03 2021
Historique:
entrez: 29 3 2021
pubmed: 30 3 2021
medline: 4 5 2021
Statut: epublish

Résumé

Radiation dosimetry is critical in the accurate delivery and reproducibility of radiation schemes in preclinical models for high translational relevance. Prior to performing any in vitro or in vivo experiments, the specific dose output for the irradiator and individual experimental designs must be assessed. Using an ionization chamber, electrometer, and solid water setup, the dose output of wide fields at isocenter can be determined. Using a similar setup with radiochromic films in the place of the ionization chamber, dose rates for smaller fields at different depths can also be determined. In vitro clonogenic survival assays of cancer cells in response to radiation treatment are inexpensive experiments that provide a measure of inherent radio-sensitivity of cell lines by fitting these data with the traditional linear-quadratic model. Model parameters estimated from these assays, combined with the principles of biologic effective doses, allows one to develop varying fractionation schedules for radiation treatment that provide equivalent effective doses in tumor-bearing animal experiments. This is an important factor to consider and correct for in comparing in vivo radiation therapy schedules to eliminate potential confounding of results due to variance in the delivered effective doses. Taken together, this article provides a general method for dose output verification preclinical animal and cabinet irradiators, in vitro assessment of radio-sensitivity, and verification of radiation delivery in small living organisms.

Identifiants

pubmed: 33779614
doi: 10.3791/61692
pmc: PMC8521631
mid: NIHMS1681907
doi:

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't Video-Audio Media

Langues

eng

Sous-ensembles de citation

IM

Subventions

Organisme : NIGMS NIH HHS
ID : U54 GM104942
Pays : United States
Organisme : NCI NIH HHS
ID : F99 CA253768
Pays : United States
Organisme : NIGMS NIH HHS
ID : P20 GM103434
Pays : United States
Organisme : NIGMS NIH HHS
ID : P20 GM121322
Pays : United States
Organisme : NIA NIH HHS
ID : T32 AG052375
Pays : United States

Références

Radiat Res. 2011 Jun;175(6):774-83
pubmed: 21449714
Nat Rev Dis Primers. 2019 Jan 17;5(1):5
pubmed: 30655533
Phys Med. 2011 Jul;27(3):122-34
pubmed: 21050785
Med Phys. 2005 Dec;32(12):3666-77
pubmed: 16475766
Cancer. 1993 Jun 1;71(11):3774-8
pubmed: 8098270
Phys Med. 2014 Feb;30(1):36-46
pubmed: 23510532
Nat Protoc. 2006;1(5):2315-9
pubmed: 17406473
Radiat Oncol. 2019 Jul 31;14(1):134
pubmed: 31366364
Radiat Oncol. 2018 Jun 1;13(1):104
pubmed: 29859114
Cell Death Differ. 2018 Mar;25(3):486-541
pubmed: 29362479
Radiat Oncol. 2018 May 16;13(1):96
pubmed: 29769103
Rev Neurosci. 2014;25(4):481-507
pubmed: 24825093
J Radiat Res. 2016 Jun;57(3):312-7
pubmed: 26951077
Int J Radiat Oncol Biol Phys. 2008 Aug 1;71(5):1591-9
pubmed: 18640502
Adv Drug Deliv Rev. 2017 Jan 15;109:1-2
pubmed: 28189183
Nat Rev Cancer. 2016 Apr;16(4):234-49
pubmed: 27009394
Radiat Res. 2012 Dec;178(6):505-23
pubmed: 23106210
Clin Oncol (R Coll Radiol). 2001;13(2):71-81
pubmed: 11373882
Br J Cancer. 2003 Dec 15;89(12):2277-83
pubmed: 14676806
CA Cancer J Clin. 2019 Jan;69(1):7-34
pubmed: 30620402
Int J Radiat Oncol Biol Phys. 2020 Feb 1;106(2):243-252
pubmed: 31288053
Z Med Phys. 2017 Mar;27(1):56-64
pubmed: 27320149
Cancer. 2005 Sep 15;104(6):1129-37
pubmed: 16080176
Med Phys. 2001 Jun;28(6):868-93
pubmed: 11439485
Clin Cancer Res. 2015 Aug 1;21(15):3393-401
pubmed: 25991820
Br J Radiol. 2010 Jul;83(991):554-68
pubmed: 20603408
Brain Behav Immun. 2020 Feb;84:115-131
pubmed: 31778743
Med Phys. 2011 Dec;38(12):6754-62
pubmed: 22149857
JAMA Oncol. 2017 Nov 1;3(11):1487-1494
pubmed: 28542679
J Cell Death. 2017 Feb 24;10:1179670717691251
pubmed: 28469473
Transl Oncol. 2016 Jun;9(3):219-27
pubmed: 27267840
Phys Med Biol. 2018 Jul 09;63(14):145001
pubmed: 29923495
Int J Radiat Oncol Biol Phys. 1994 Jan 15;28(2):355-62
pubmed: 8276650
Int J Radiat Biol. 1994 Jul;66(1):49-57
pubmed: 8027612
Radiat Oncol. 2017 Dec 28;12(1):204
pubmed: 29282134
Oncotarget. 2017 Jun 8;8(37):62742-62758
pubmed: 28977985
Phys Med Biol. 2020 Jan 13;65(1):015012
pubmed: 31775123

Auteurs

Samuel A Sprowls (SA)

Department of Basic Pharmaceutical Sciences, School of Pharmacy, West Virginia University.

Vincenzo J Pizzuti (VJ)

Department of Basic Pharmaceutical Sciences, School of Pharmacy, West Virginia University; School of Medicine, West Virginia University.

William Pentz (W)

Department of Basic Pharmaceutical Sciences, School of Pharmacy, West Virginia University.

Divine C Nwafor (DC)

School of Medicine, West Virginia University; Department of Neuroscience, West Virginia University.

R Alfredo C Siochi (RAC)

Radiation Oncology, West Virginia University; School of Medicine, West Virginia University.

Paul R Lockman (PR)

Department of Basic Pharmaceutical Sciences, School of Pharmacy, West Virginia University; prlockman@hsc.wvu.edu.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH